2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-13604S1
    Cyproterone acetate-d6
    Cyproterone acetate-d6 is the deuterium labeled Cyproterone acetate (HY-13604). Cyproterone acetate is an anti-androgen (IC50=7.1 nM) and progestogen synthetic steroid. Cyproterone acetate has affinity with progesteron and with glucocorticoidal receptors.
    Cyproterone acetate-d6
  • HY-136438R
    Toltrazuril sulfoxide (Standard) 69004-15-5
    Toltrazuril sulfoxide (Standard) is the analytical standard of Toltrazuril sulfoxide. This product is intended for research and analytical applications. Toltrazuril sulfoxide is a short-lived intermediary metabolite of Toltrazuril (HY-B0175), and then can be metabolized to the reactive toltrazuril sulfone (TZR-SO2) in vivo. Toltrazuril is an antiprotozoal agent that acts upon Coccidia parasites.
    Toltrazuril sulfoxide (Standard)
  • HY-136520A
    (R)-Xanthoanthrafil 247568-68-9 98%
    (R)-Xanthoanthrafil is a phosphodiesterase-5 (PDE5) inhibitor. (R)-Xanthoanthrafil selectively inhibits PDE5, increasing cyclic guanosine monophosphate (cGMP) levels, leading to smooth muscle relaxation and promoting penile erection. (R)-Xanthoanthrafil can be used to study erectile dysfunction.
    (R)-Xanthoanthrafil
  • HY-137258A
    (R)-N-3-Benzylnirvanol 790676-41-4 98%
    (R)-N-3-Benzylnirvanol is the R-isomer of (±)-N-3-Benzylnirvanol (HY-137258). (±)-N-3-Benzylnirvanol is a racemic mixture of (+)-N-3-Benzylnirvanol and (-)-N-3-Benzylnirvanol. (+)-N-3-Benzylnirvanol and (–)-N-3-Benzylnirvanol are potent and selective cytochrome P450 inhibitors with Ki values of 0.25 and 5.3 μM for CYP2C19, respectively.
    (R)-N-3-Benzylnirvanol
  • HY-137390A
    (3S,5R)-Fluvastatin potassium 1009811-63-5 98%
    (3S,5R)-Fluvastatin (potassium) is a synthetic hypolipidemic drug that inhibits HMG-CoA reductase activity. (3S,5R)-Fluvastatin (potassium) has similar antioxidative effects on copper ion-induced LDL oxidation compared to its 3R,5S enantiomer. (3S,5R)-Fluvastatin (potassium) and its metabolites demonstrate a potential to exhibit anti-atherosclerotic effects through their antioxidative activities. (3S,5R)-Fluvastatin (potassium) is clinically utilized as part of a racemic mixture for reducing plasma cholesterol levels.
    (3S,5R)-Fluvastatin potassium
  • HY-13749S2
    Sitagliptin-d4 98%
    Sitagliptin-d4 (MK-0431-d4) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.
    Sitagliptin-d4
  • HY-137593A
    N6-Etheno-nicotinamide dinucleotide phosphate trisodium 98%
    N6-Etheno-nicotinamide dinucleotide phosphate (ε-NADP+) trisodium, a structural analogue of the NADP(+), is a maize malic enzyme inhibitor with a Ki of 1.01 μM.
    N6-Etheno-nicotinamide dinucleotide phosphate trisodium
  • HY-137603A
    Uridine-5'-O-3-thiotriphosphate tetrasodium 98%
    Uridine-5'-O-(3-thiotriphosphate) (UTPγS) tetrasodium, a stable analogue of Uridine triphosphate (UTP) (HY-107372), is a potent agonist of the P2Y2 and P2Y4 receptors with increased metabolic stability. Uridine-5'-O-(3-thiotriphosphate) tetrasodium stimulates inositol phosphate formation in human 1321N1 astrocytoma cells stably expressing the phospholipase C-coupled human P2U-purinoceptor (EC50 = 240 nM).
    Uridine-5'-O-3-thiotriphosphate tetrasodium
  • HY-137626C
    Rp-ATPαS tetrasodium 661465-43-6 98%
    Rp-ATPαS is a monomeric raw material that can be used for nucleic acid synthesis.
    Rp-ATPαS tetrasodium
  • HY-137638A
    Sp-5,6-DCl-cBIMPS sodium 142439-96-1 98%
    Sp-5,6-DCl-cBIMPS sodium is a potent and specific cAMP-dependent protein kinases (cAMP-PK) activator. Sp-5,6-DCl-cBIMPS sodium stimulates insulin release. Sp-5,6-DCl-cBIMPS sodium inhibits U-46619 (HY-108566)-induced activation of Rho, Gq and G12/G13 in platelets.
    Sp-5,6-DCl-cBIMPS sodium
  • HY-137662A
    5'-Phosphoguanylyl-(3',5')-guanosine trisodium 98%
    5'-Phosphoguanylyl-(3',5')-guanosine trisodium (pGpG trisodium) is an intermediate molecule produced by the pathway for enzymatic cyclic diguanylate (c-di-GMP) degradation. 5'-Phosphoguanylyl-(3',5')-guanosine trisodium can be used to detect the metabolism of nucleic acids.
    5'-Phosphoguanylyl-(3',5')-guanosine trisodium
  • HY-137675A
    isoGDP trisodium 98%
    isoGDP (trisodium) is a GDP isomer. isoGDP (trisodium) is a phosphorylated form of crotonoside. isoGDP (trisodium) is an inhibitor of mitochondrial ATPase with an IC50 of 3 μM.
    isoGDP trisodium
  • HY-13777AR
    Zoledronic acid monohydrate (Standard) 165800-06-6
    Zoledronic acid (monohydrate) (Standard) is the analytical standard of Zoledronic acid (monohydrate). This product is intended for research and analytical applications. Zoledronic acid monohydrate (Zoledronate monohydrate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic acid monohydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic acid monohydrate also has anti-cancer effects.
    Zoledronic acid monohydrate (Standard)
  • HY-137813S
    PERK-IN-4-d3 98%
    PERK-IN-4-d3 is the deuterium labeled PERK-IN-4. PERK-IN-4 is a potent and selective PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase) inhibitor with an IC50 of 0.3 nM. PERK is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states.
    PERK-IN-4-d3
  • HY-137846A
    PF-05221304 tromethamine 2334472-62-5
    PF-05221304 tromethamine is an orally active, liver-directed and dual ACC1/ACC2 inhibitor with IC50s of 7.5 nM for rat ACC1, 8.2 nM for rat ACC2. PF-05221304 tromethamine is a substrate for organic anion transport polypeptides. PF-05221304 tromethamine directly improves a variety of non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) pathogenic factors.
    PF-05221304 tromethamine
  • HY-138119A
    γ-Glutamylserine TFA 98%
    γ-Glutamylserine TFA (γ-Glu-Ser TFA) is a calcium receptor activator. γ-Glutamylserine TFA can be used for Parkinson's disease research, as well as diabetes or obesity study.
    γ-Glutamylserine TFA
  • HY-138443A
    BF-175 1333375-02-2
    BF-175 is a selective SIRT1 agonist. BF175 increases SIRT1-mediated activation of PGC1-α, induces Apoptosis, induces Autophagy and inhibits SREBP activity. BF-175 protects against high glucose-mediated mitochondrial injury. BF-175 attenuates diabetic kidney disease progression. BF175 inhibits endometrial carcinoma.
    BF-175
  • HY-138815S
    (S)-N-(1H-Indole-3-acetyl)tryptophan-d4 98%
    (S)-N-(1H-Indole-3-acetyl)tryptophan-d4 is deuterium labeled (S)-N-(1H-Indole-3-acetyl)tryptophan. (S)-N-(1H-Indole-3-acetyl)tryptophan (compound 4a) is a Tryptophan derivative that weakly inhibits β-D-glucosidase.
    (S)-N-(1H-Indole-3-acetyl)tryptophan-d4
  • HY-139058R
    23-epi-26-Deoxyactein (Standard) 501938-01-8
    23-epi-26-Deoxyactein (Standard) is the analytical standard of 23-epi-26-Deoxyactein. This product is intended for research and analytical applications. 23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound.
    23-epi-26-Deoxyactein (Standard)
  • HY-139409B
    2-Deoxy-D-glucose 6-phosphate sodium
    2-Deoxy-D-glucose 6-phosphate sodium, a derivative of 2-Deoxy-D-glucose (HY-13966), is produced in mammalian cells by the action of hexokinase on 2-DG. 2-Deoxy-D-glucose is a glucose analog that acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis via its actions on hexokinase.
    2-Deoxy-D-glucose 6-phosphate sodium
Cat. No. Product Name / Synonyms Application Reactivity